The rationale for re-administration of genetically engineered biological drugs in patients with COVID-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, there are no evidence-based data to recommend the use of repeated doses of interleukin-6 (IL-6) blockers for the treatment of patients with COVID-19. To date, the data on the effectiveness of IL-6 blockers are contradictory. The use of drugs of this group can increase the risk of suppression of the immune system with a decrease in resistance to infectious agents.

Full Text

Restricted Access

About the authors

I. S Burashnikova

Kazan State Medical Academy - Branch Campus of the Russian Medical Academy of Continuous Professional Education

Kazan, Russia

References

  1. Zhang Q, Bastard P., Liu Z. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi: 10.1126/SCIENCE.ABD4570.
  2. Bastard P., Rosen L.B., Zhang Q. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/SCIENCE.ABD4585.
  3. Xu Z., Shi L., Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet. Resp Med. 2020;8(4):420-422. doi.org/10.1016/S2213-2600(20)30076-X
  4. Trouillet-Assant S., Viel S., Gaymard A., et al. COVID HCL Study group. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol. 2020;146(1):206-8.e2. Doi: 10.1016/j. jaci.2020.04.029.
  5. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. COVID-19 Host Genetics Initiative. Eur J Hum Genet. 2020;28(6):715-18. doi: 10.1038/s41431-020-0636-6.
  6. Huang C, Wang Y, Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
  7. Jakhmola S, Indari O, Chatterjee S, Jha HC. SARS-CoV-2, an Underestimated Pathogen of the Nervous System. SN Compr Clin Med. 2020 Sep 28:1-10. doi: 10.1007/s42399-020-00522-7. Epub ahead of print. PMID: 33015550; PMCID: PMC7520376.
  8. Del Valle D.M., Kim-Schulze S., Huang H.H., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-43. doi: 10.1038/s41591-020-1051-9.
  9. Laing A.G., Lorenc A., Del Molino Del Barrio I., et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26(10):1623-35. Doi: 10.1038/ s41591-020-1038-6.
  10. Hyder Pottoo F., Abu-Izneid T, Mohammad Ibrahim A., et al. Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19. Saudi Pharm J. 2021;29(2):173-87. Doi: 10.1016/j. jsps.2020.12.018.
  11. Liuzzo G, Patrono C. COVID 19: in the eye of the cytokine storm. Eur Heart J. 2021;42(2):150-51. doi: 10.1093/eurheartj/ehaa1005.
  12. Feldmann M., Maini R.N., Woody J.N., et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 395(10234):1407-409. Doi: 10.1016/ S0140-6736(20)30858-8.
  13. Йокота Ш., Куройва Е., Нишиока К. Новая коронавирусная болезнь (COVID-19) и «цитокиновый шторм». Перспективы эффективного лечения с точки зрения патофизиологии воспалительного процесса. Инфекционные болезни: новости, мнения, обучение. 2020;9(4):1325
  14. Профилактика, диагностика и лечение новой коронавирусной инфекции COVID-19. Версия 11 (07.05.2021)
  15. https://app.magicapp.org/ff/guideline/L4Q5An/ rec/Lq4Y0j
  16. Khani E., Khiali S., Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. J Clin Pharmacol. 2021;61(4):429-60. doi: 10.1002/jcph.1822.
  17. Siemieniuk R.A., Bartoszko J.J., Ge L., et al. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. doi: 10.1136/bmj.m2980.
  18. Клинический протокол лечения больных новой коронавирусной инфекцией COVID-19, находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. 2020.
  19. URL: https://COVID19evidence.net.au/ffliving-guidelines
  20. URL: https://app.magicapp.org/ff/guideline/ L4Q5An/rec/jMxdW
  21. URL: https://rsmu.ru/fileadmin/templates/DOC/ Faculties/LF/gt2/COVID-19/Ispanskii_protokol_ klinicheskogo_vedenija_pacientov_s_COVID-19. pdf (первоисточник не найден/original source not found).
  22. Xu X., Han M., Li T., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970-75. doi: 10.1073/pnas.2005615117.
  23. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (7th Interim Edition). China NHCOTPSRO. URL: http://www.nhc.gov.cn/ yzygj/s7653p/202003/46c9294a7dfe4cef80dc 7f5912eb1989/files/ce3e6945832a438eaae41 5350a8ce964.pdf
  24. Luo P., Liu Y, Qiu L., et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-18. doi: 10.1002/jmv.25801.
  25. Zhang, X., et al., First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307-10. doi: 10.1182/bloodadvances.2020001907.
  26. Pilot, Randomized, Multicenter, Open-label Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19). URL: https:// clinicaltrials.gov/ct2/show/study/NCT04332094
  27. Rosas I.O., Bru N., Waters M., et al. Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia. N EnglJ Med. 2021:NEJMoa2028700. doi: 10.1056/NEJMoa2028700.
  28. Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study. URL:https://clinicaltrials.gov/ct2/ show/NCT04310228?term=NCT04310228&dra w=2&rank=1.
  29. Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients -Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI). URL: https://clinicaltrials. gov/ct2/show/results/NCT04331808?term=NCT 04331808&draw=2&rank=1&view=results
  30. Hermine O., Mariette X., Tharaux PL., et al. CORIMUNO-19 Collaborative Group. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA. Intern. Med. 2021;181(1):32-40. Doi: 10.1001/ jamainternmed.2020.6820. Erratum in: JAMA Intern Med. 2021;181(1):144.
  31. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 20211;397(10285):1637-doi: 10.1016/S0140-6736(21)00676-0.
  32. Gordon A.C., Mouncey P.R., Al-Beidh F., et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19 - Preliminary report The REMAP-CAP Investigators. medRxiv. 2021.01.07.21249390. doi: 10.1101/2021.01.07.21249390.
  33. URL:https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=4ebb0265-ade9-41c5-b63c-e37936eacc8b&t=

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies